ArticleMolecular cancer therapeutics2026

Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors.

Azadeh C Bashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.